DAWN - Day One Biopharma climbs over 15% a post-IPO record

After a decline of more than 10% on Wednesday, Day One Biopharmaceuticals (DAWN +18.4%) is trading sharply higher to post the biggest intraday gain since its IPO in May. About 113.7K company shares have changed hands compared to the 65-day average volume of ~105.1K shares. The small-cap biotech company surged on its trading debut after pricing its public offering at $16 per share for $160M in gross proceeds. The clinical-stage company focused on genetically driven cancers is advancing its lead asset DAY101 in mid-stage studies as a potential therapy for relapsed/progressive low-grade glioma (pLGG) in children and for solid tumors in adults with MAPK pathway aberrations. The patient enrollment of its registrational Phase 2 trial for children with pLGG is currently underway, Day One (NASDAQ:DAWN) said in November. The initial data from the trial are expected in H1 2022, the company added.

For further details see:

Day One Biopharma climbs over 15%, a post-IPO record